PTEN-deficient cancers depend on PIK3CB

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 13057-13062

  Wee, Susan ^a   Wiederschain, Dmitri ^a   Maira, Sauveur Michel ^b   Loo, Alice ^a   Miller, Christine ^a   DeBeaumont, Rosalie ^a   Stegmeier, Frank ^a   Yao, Yung Mae ^a   Lengauer, Christoph ^a,c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA; PHOSPHATIDYLINOSITOL 3 KINASE CB; PHOSPHATIDYLINOSITOL 3 KINASE CD; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P110; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE MUTATION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASMS; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 51349148948     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0802655105     Document Type: Article

References (41)

1. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
2. Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133:403-414.
3. Chen M-L, et al. (2006) The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice10.1101/gad. 1395006. Genes Dev 20:1569-1574.
4. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 22:6289-6295.
5. +/- mice. Curr Biol 15:1839-1846.
6. Li J, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated inhuman brain, breast, and prostate cancer. Science 275:1943-1947.
7. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378.
8. Steck PA, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
9. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
10. Campbell IG, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681.
11. Bachman KE, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775.
12. Lee JW, et al. (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477-1480.
13. Levine DA, et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11:2875-2878.
14. Wu G, et al. (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7:R609-R616.
15. Parsons DW, et al. (2005) Colorectal cancer: Mutations in a signalling pathway. Nature 436:792.
16. Saal LH, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559.
17. Abubaker J, et al. (2007) PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21:2368-2370.
18. Wang Y, et al. (2007) High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92:2387-2390.
19. Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669-10673.
20. Maira SM, Voliva C, Garcia-Echeverria C (2008) Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 12:223-238.
21. Cohen P (2002) Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315.
22. Zhao JJ, Roberts TM. 2006. PI3 kinases in cancer: From oncogene artifact to leading cancer target. Sci STKE 2006:pe52.
23. Wymann MP, Pirola L (1998) Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1436:127-150.
24. Stauffer F, Maira SM, Furet P, Garcia-Echeverria C (2008) Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg Med Chem Lett 18:1027-1030.
25. Raynaud FI, et al. (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840-5850.
26. Okkenhaug K, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297:1031-1034.
27. Foukas LC, et al. (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-370.
28. Jackson SP, et al. (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11:507-514.
29. McMullen JR, et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110{alpha}) signaling in dilated and hypertrophic cardiomyopathy. PNAS 104:612-617.
30. Wee S, Lengauer C, Wiederschain D (2008) Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: Implications for cancer drug discovery and development. Curr Opin Oncol 20:77-82.
31. Samuels Y, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561-573.
32. Cairns P, et al. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000.
33. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G (1998) PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16:541-545.
34. Feilotter HE, et al. (1999) Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79:718-723.
35. Torbett NE, et al. (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. Biochem J, 10.1042/BJ20080639.
36. Sadhu C, Dick K, Tino WT, Staunton DE (2003) Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun 308:764-769.
37. Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104-107.
38. Beeton CA, Chance EM, Foukas LC, Shepherd PR (2000) Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases. Biochem J 350 Pt 2:353-359.
39. Kubo H, Hazeki K, Takasuga S, Hazeki O (2005) Specific role for p85/p110beta in GTP-binding-protein-mediated activation of Akt. Biochem J 392:607-614.
40. Kurosu H, et al. (1997) Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. J Biol Chem 272:24252-24256.
41. Jia S, et al. 2008. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature, 10.1038/nature07091.